Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

p53, CHK2, and CHK1 Genes in Finnish Families with Li-Fraumeni Syndrome: Further Evidence of CHK2 in Inherited Cancer Predisposition

p53, CHK2, and CHK1 Genes in Finnish Families with Li-Fraumeni Syndrome: Further Evidence of CHK2... Germ-line mutations in the p53 gene predispose individuals to Li-Fraumeni syndrome (LFS). The cell cycle checkpoint kinases CHK1 and CHK2 act upstream of p53 in DNA damage responses, and recently rare germ-line mutations in CHK2 were reported in LFS families. We have analyzed CHK1 , CHK2 , and p53 genes for mutations in 44 Finnish families with LFS, Li-Fraumeni-like syndrome, or families phenotypically suggestive of LFS with conformation-sensitive gel electrophoresis. Five different disease-causing mutations were observed in 7 families (7 of 44 families; 15.9%): 4 in the p53 gene (5 of 44 families; 11.4%) and 1 in the CHK2 gene (2 of 44 families; 4.5%). Interestingly, the other CHK2 -mutation carrier also has a mutation in the MSH6 gene. The cancer phenotype in the CHK2 -families was not characteristic of LFS, and may indicate variable phenotypic expression in the rare families with CHK2 mutations. No mutations in the CHK1 gene were identified. Additional work is necessary to completely unravel the molecular background of LFS. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cancer Research American Association of Cancer Research

p53, CHK2, and CHK1 Genes in Finnish Families with Li-Fraumeni Syndrome: Further Evidence of CHK2 in Inherited Cancer Predisposition

p53, CHK2, and CHK1 Genes in Finnish Families with Li-Fraumeni Syndrome: Further Evidence of CHK2 in Inherited Cancer Predisposition

Cancer Research , Volume 61 (15): 5718 – Aug 1, 2001

Abstract

Germ-line mutations in the p53 gene predispose individuals to Li-Fraumeni syndrome (LFS). The cell cycle checkpoint kinases CHK1 and CHK2 act upstream of p53 in DNA damage responses, and recently rare germ-line mutations in CHK2 were reported in LFS families. We have analyzed CHK1 , CHK2 , and p53 genes for mutations in 44 Finnish families with LFS, Li-Fraumeni-like syndrome, or families phenotypically suggestive of LFS with conformation-sensitive gel electrophoresis. Five different disease-causing mutations were observed in 7 families (7 of 44 families; 15.9%): 4 in the p53 gene (5 of 44 families; 11.4%) and 1 in the CHK2 gene (2 of 44 families; 4.5%). Interestingly, the other CHK2 -mutation carrier also has a mutation in the MSH6 gene. The cancer phenotype in the CHK2 -families was not characteristic of LFS, and may indicate variable phenotypic expression in the rare families with CHK2 mutations. No mutations in the CHK1 gene were identified. Additional work is necessary to completely unravel the molecular background of LFS.

Loading next page...
 
/lp/american-association-of-cancer-research/p53-chk2-and-chk1-genes-in-finnish-families-with-li-fraumeni-syndrome-E0Vuy54IE3

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
American Association of Cancer Research
Copyright
Copyright © 2001 by the American Association for Cancer Research.
ISSN
0008-5472
Publisher site

Abstract

Germ-line mutations in the p53 gene predispose individuals to Li-Fraumeni syndrome (LFS). The cell cycle checkpoint kinases CHK1 and CHK2 act upstream of p53 in DNA damage responses, and recently rare germ-line mutations in CHK2 were reported in LFS families. We have analyzed CHK1 , CHK2 , and p53 genes for mutations in 44 Finnish families with LFS, Li-Fraumeni-like syndrome, or families phenotypically suggestive of LFS with conformation-sensitive gel electrophoresis. Five different disease-causing mutations were observed in 7 families (7 of 44 families; 15.9%): 4 in the p53 gene (5 of 44 families; 11.4%) and 1 in the CHK2 gene (2 of 44 families; 4.5%). Interestingly, the other CHK2 -mutation carrier also has a mutation in the MSH6 gene. The cancer phenotype in the CHK2 -families was not characteristic of LFS, and may indicate variable phenotypic expression in the rare families with CHK2 mutations. No mutations in the CHK1 gene were identified. Additional work is necessary to completely unravel the molecular background of LFS.

Journal

Cancer ResearchAmerican Association of Cancer Research

Published: Aug 1, 2001

There are no references for this article.